ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BXP Beximco Pharma

39.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Beximco Pharma LSE:BXP London Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 39.00 37.00 41.00 39.00 38.00 39.00 5,319 08:00:06

Beximco Pharmaceuticals Ltd AGM Change and Dividend Update (4112X)

06/05/2016 7:01am

UK Regulatory


Beximco Pharma (LSE:BXP)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Beximco Pharma Charts.

TIDMBXP

RNS Number : 4112X

Beximco Pharmaceuticals Ltd

06 May 2016

BEXIMCO PHARMACEUTICALS LTD.

6 May 2016

Postponement of Annual General Meeting and Dividend update

("Beximco Pharma", "BPL" or "the Company")

Beximco Pharmaceuticals Ltd. (AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces that, as a consequence of its change of accounting reference date to 30 June announced today, the 40(th) Annual General Meeting of the Company ("AGM"), declared for 4 June 2016 is hereby postponed. The AGM will now be held before the end of this calendar year and will consider, inter alia, the adoption of the Company's audited report and accounts for the 18 month period ending on 30 June 2016, which is the new financial year end of the Company.

In addition, in the preliminary results announcement dated 21 April 2016, the Company made certain announcements in relation to dividends relating to the 12 month period ended 31 December 2015.

As a result of the change of the accounting reference date and the postponement of the AGM, the Company now wishes to clarify the following:

-- That the record date for entitlement of 10% cash and 5% stock dividend, which was declared to be 12 May 2016, shall remain unchanged; and

-- That the 10% cash dividend declared by the Company, will be paid on or before 4 July, 2016. The 5% Stock dividend will be issued subject to the approval of the shareholders at the forthcoming AGM.

Ends

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel: +880 2 58611891, +880 2 58612040, Ext 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Sean Wyndham-Quin

Tel: +44 (0)20 3368 3551 / 3555

Daniel Stewart & Company plc (Broker)

Martin Lampshire

Tel: +44 (0)20 7776 6550

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000

Notes to Editors:

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, Europe, Latin America, Canada and the US, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia and Nigeria; Pacific Island; Latin and Central American countries; Middle East; Central Asia; South East Asia, including Singapore, Malaysia, Indonesia, Philippines and Hong Kong; Europe, including Austria, Germany and Romania and Australia.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUAGAUPQGCA

(END) Dow Jones Newswires

May 06, 2016 02:01 ET (06:01 GMT)

1 Year Beximco Pharma Chart

1 Year Beximco Pharma Chart

1 Month Beximco Pharma Chart

1 Month Beximco Pharma Chart

Your Recent History

Delayed Upgrade Clock